Navigation Links
CryoLife Posts Record Annual Revenues of $116.6 Million
Date:2/17/2011

us from succeeding in the execution of our strategies.  Also, any expansion of product offerings may not be accepted by surgeons and patients, thereby preventing us from reaping the anticipated benefits of future investments.  Business development expenses may be more than anticipated.  Our ability to successfully distribute our remaining inventory of HemoStase may be impacted by the success of competitors in the market and our sales of PerClot.  We may ultimately sell significantly less than currently expected of our remaining HemoStase inventory.  Medafor may take action to attempt to prevent us from being able to continue to distribute HemoStase through late March 2011.  The date of our trial with Medafor will be set by the court and is beyond our control.  Estimated expenses in fiscal 2011 may be greater than those included in our fiscal 2011 guidance if we are successful in continuing to realize on our business development strategy and acquire additional complementary products or businesses, or if unexpected events, such as the need for further inventory write-downs, occur in fiscal 2011.  Our anticipated performance for the full year of fiscal 2011 is subject to the general risks associated with our business, including that we are significantly dependent on our revenues from BioGlue and are subject to a variety of risks affecting this product, including that a German Patent Court has nullified our main BioGlue patent in Germany, and if the ruling is upheld on appeal, we would be prevented from suing to prevent third parties from infringing the main BioGlue patent in Germany, we are subject to stringent domestic and foreign regulation which may impede the approval process of our tissues and products, hinder our development activities and manufacturing processes, and, in some cases, result in the recall or seizure of previously cleared or approved tissues and products, we expect HemoStase sales to cease in late Mar
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. CryoLife Announces Release Date and Teleconference Call Details for 2010 Fourth Quarter and Year End Financial Results
2. CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
3. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
4. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
5. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
6. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
7. CryoLife Provides Initial 2010 Financial Guidance
8. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
9. CryoLife to Present at Upcoming Investor Conferences in New York
10. CryoLife Reports Record Quarterly Revenues of $28.2 Million
11. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 EspeRare today announced ... Orphan Drug Designation (ODD) for rimeporide, its lead compound ... is a rare, life-threatening disease affecting boys early in ... is the most common and serious form of paediatric ... exchanger type-1 inhibitor, originally developed by Merck Serono in ...
(Date:5/1/2015)... The breakthrough hepatitis C treatment, Sovaldi faced ... Gilead Sciences overcame initial market resistance through its patient ... campaigns. Sovaldi,s high cure rate, short dosing ... the drug to $2.3 billion in sales during the ... the market. But Sovaldi,s price tag of $84,000 was ...
(Date:5/1/2015)... 1, 2015 Hitachi Chemical Diagnostics, Inc. is ... launch of the ExoComplete™ 96-Well Plate Kit and ... for exosome collection to mRNA purification.  The products were ... Annual Meeting, April 23 – 26, 2015, in ... for research use only of molecular biology applications and ...
Breaking Medicine Technology:EspeRare's Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy 2New Study Examines Success Lessons of Sovaldi's and Harvoni's Blockbuster Launches 2New Products for Exosome Isolation to mRNA Purification 2
... N.J., Oct. 19, 2011 Pacira Pharmaceuticals, Inc. ... data demonstrating a reduction in opioid burdens with EXPAREL™ ... and including 300 mg compared to bupivacaine HCl in ... the American College of Clinical Pharmacy (ACCP) in Pittsburgh. ...
... York eHealth Collaborative (NYeC) today announced the winners of its ... to the world of health information technology and healthcare. The ... NYeC Digital Health Conference 2011 on Thursday, Dec. 1. ... leading the advancement of health IT in New York State," ...
Cached Medicine Technology:Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 2Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 3Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 4Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 5Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 6New York eHealth Collaborative Announces Winners for its Digital Health Conference Gala Awards 2
(Date:5/4/2015)... CCL, a top-ranked, global provider of ... to other leadership development consultancies. “The CCL Partner ... successful practitioners, expanding our capacity to drive results for ... R. Ryan, CCL President and CEO. , As soon ... Network , it will schedule a one-on-one conference with ...
(Date:5/4/2015)... Diego, CA (PRWEB) May 04, 2015 ... a ribbon cutting ceremony at their brand new, 13,700 ... this year. The new building will not only provide ... population, but will also offer community and educational events ... The new facility is located next door to their ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Dr. Benjamin ... Georgia proudly offers the latest non-surgical double-chin eliminator. ... facial plastic surgeon in Atlanta to offer Kybella ... to be injected specifically under the chin, promising to ... , Before Kybella, patients who sought immediate solutions for ...
(Date:5/4/2015)... Unlike some camps, the Nike Middle School Running Camps are focused ... educate first and train second, with a significant amount of time ... are building the knowledge base needed to have a long and ... Effort Based Training, Running Heroes, Running Vocabulary, and Why am I ... not a camp where kids come to run and train hard ...
(Date:5/4/2015)... Dr. Richard Champagne, DMD, MAGD is pleased ... the America’s Best Dentist Award, given by the National ... top dentist is a reflection of his vast experience ... compassion for his patients. , Each year, the National ... their field. These nominees are dentists who have exceptionally ...
Breaking Medicine News(10 mins):Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2
... a daily basis has been stepped up in China, the ... out breaks of the much dreaded Avian influenza or “bird ... north-west regions two weeks ago. China has accelerated efforts to ... monitoring stations. The public at large and officials have been ...
... with a family history of lung cancer may be at ... new study. // ,Jun-Ichi Nitadori and colleagues at ... they looked into the health of more than 102,000 Japanese ... study, reported the online edition of health magazine WebMD. ...
... Injecting gold into knees affected by osteoarthritis may ease pain and ... it does not help everyone with rheumatoid arthritis. ,Arthritis ... the joints of the body. It is the leading cause of ... arthritis, each of which has a different cause. ,Researchers ...
... to shift gears and use decaffeinated coffee to avoid caffeine ... recent research and data compiled by the University of Florida ... caffeine. ,This month's Journal of Analytical Toxicology. has ... ,coffee which is one of the most prominent sources of ...
... all Public Offices across Bangkok the capital city of ... a senior official from the Bangkok Metropolitan Administration. ... Thai News Agency that the initial reforms have been ... BMA’s headquarters where smoking has already been prohibited in ...
... new survey showed that the total spending on Medicaid has ... was a reflection of a better economy// that has held ... federal Medicare drug benefit, according to a new survey. ,Medicaid ... has shown a growth of 2.8 percent in fiscal 2006, ...
Cached Medicine News:Health News:Decaffeinated Coffee... Not Really! 2Health News:Lowest Spending growth in US Medicaid 2
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Smooth pointed tips open to 3.0 mm. 45 degree cross action angled shafts. Tip to Angle Length: 12.0 mm. Round handle....
Flat handle 9 mm wide, angulated 45....
Straight shafts with pointed tips and 6 mm tying platform. Smooth handle with dull finish. Fine pointed tips....
Medicine Products: